1. Home
  2. KRUS vs BDTX Comparison

KRUS vs BDTX Comparison

Compare KRUS & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$39.31

Market Cap

539.2M

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.88

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
BDTX
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
539.2M
171.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
KRUS
BDTX
Price
$39.31
$1.88
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
★ $81.11
$9.67
AVG Volume (30 Days)
218.8K
★ 513.0K
Earning Date
04-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
★ 130.71
EPS
N/A
★ N/A
Revenue
★ $282,763,000.00
N/A
Revenue This Year
$20.50
N/A
Revenue Next Year
$20.68
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.88
N/A
52 Week Low
$33.97
$1.60
52 Week High
$80.84
$4.94

Technical Indicators

Market Signals
Indicator
KRUS
BDTX
Relative Strength Index (RSI) 42.70 39.32
Support Level $33.97 $1.76
Resistance Level $59.30 $1.90
Average True Range (ATR) 1.88 0.08
MACD 0.44 -0.02
Stochastic Oscillator 63.85 20.00

Price Performance

Historical Comparison
KRUS
BDTX

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: